A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
Recruiting now Phase 2 NCT06979336
Run by Genentech, Inc. · for 18 and older · All sexes
What this study is about
The purpose of this study is to evaluate the efficacy of RO7837195 compared with placebo in participants with moderately to severely active ulcerative colitis for whom prior treatment with conventional and/or advanced therapies has failed.
Who can join (things the study team will check)
✅ You may be able to join if…
- Diagnosis of ulcerative colitis (UC) established at least 3 months
- Moderately to severely active UC assessed by mMS
- Inadequate response, loss of response, or intolerance to conventional or advanced therapies for UC
🚫 You may not be able to join if…
- Prior extensive colonic resection, subtotal or total colectomy, or planned surgery for UC
- Diagnosis of Crohn's disease or indeterminate colitis
- Treatment with an advanced therapy targeted at tumor necrosis factor-like cytokine 1A (TL1a)
- Inadequate response, loss of response, or intolerance to treatment of UC with an advanced therapy targeted at IL-12 and/or IL-23
Where this trial is running
- Gastro Care Institute, Lancaster, California, United States
- Medical Associates Research Group, Inc., San Diego, California, United States
- Peak Gastroenterology Associates, Colorado Springs, Colorado, United States
- Clinical Research of Osceola, LLC, Kissimmee, Florida, United States
- University of Chicago Medical Center, Chicago, Illinois, United States
- Intercity Gastroenterology, Fresh Meadows, New York, United States
- Monroe Biomedical Research, Monroe, North Carolina, United States
- University of Utah Hospitals & Clinics, Salt Lake City, Utah, United States
- Mater Misericordiae Limited, South Brisbane, Queensland, Australia
- HUWC - UFC - Hospital Universitrio Walter Cantdio - Universidade Federal do Cear, Fortaleza, Ceará, Brazil
- L2IP ?Instituto de Pesquisas Clínicas Ltda., Brasília, Federal District, Brazil
- Chronos Pesquisa Clinica, Brasília, Federal District, Brazil
+ 89 more sites.
Who to contact
Reference Study ID Number: GA45977 https://forpatients.roche.com/ No attachments to email below. · 888-662-6728 (U.S.) · global-roche-genentech-trials@gene.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06979336.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.